ABBOTT LABORATORIES

ABBOTT LABORATORIES (ABT) — Investment Memo

🐂 The Bull Case (Warren's voice)

• Moat is real and widening – switching costs in Diabetes Care (Freestyle Libre) and structural heart (MitraClip) keep customers locked in. Regulatory approval cycles are multi-year barriers. The installed base of sensors and implantables grows each year, generating recurring revenue that compounds as the diabetic and aging populations expand.
• Economics are exceptional in the best segment – Medical Devices, now the largest division, runs at estimated 30%+ operating margins thanks to sticky consumables. Free cash flow has grown from $2.1B to $7.4B over a decade – real cash, not accounting tricks. The mix shift away from low-margin generics toward high-margin devices is a structural tailwind.
• Attractive entry price at a 25% discount to intrinsic value – The DCF yields an intrinsic value of $150.49 per share. At $112.87 (25% margin of safety), the business is genuinely cheap relative to its durable competitive position and long-duration cash flows. Berkshire should act when Mr. Market offers a clear gap between price and value.

🐻 The Bear Case (Charlie inverts)

Munger's rule: "Show me where I'll die and I won't go there."

• Scenario #1: Non‑invasive CGM disruption. A painless, cheap, wearable sensor (optical or sweat‑based) that eliminates the needle‑free Freestyle Libre sensor. Abbott’s $5B+ recurring revenue stream in Diabetes Care could vanish overnight. A startup like Apple or Dexcom (with next‑gen tech) is the most likely killer – and the most probable structural threat within 5–10 years.
• Scenario #2: U.S. government price caps on diabetes devices. If Medicare/Medicaid or private insurers impose price controls on continuous glucose monitors (CGM) as a cost‑cutting measure, Abbott’s highest‑margin product gets crushed. Marginal economics collapse; the moat becomes a cost‑center. This is a medium‑probability, high‑severity risk, especially under shifting healthcare policy within 3–7 years.
• Scenario #3: Currency and geopolitical erosion of 60%+ foreign revenue. Abbott’s Emerging Markets pharmaceutical business faces constant price pressure, and a strong dollar or trade disruptions (India, China, Russia) can permanently impair earnings. This is a slow bleed, not a sudden death – but over 10–15 years it can shrink the moat’s real compounding. The most likely bear case? CGM disruption – because technology moves faster than regulation.

💰 Valuation & Margin of Safety

• Intrinsic value estimate: $150.49 per share (DCF with 14.8% FCF growth, 10% discount rate, 3% terminal growth). This is a fair approximation, but the one‑time 2024 earnings spike inflates the base – real normalised FCF is closer to $7.0B, which supports a similar valuation.
• 25% margin of safety entry: $112.87 – conservative, where the business is clearly undervalued given its moat and cash generation.
• 50% margin of safety entry: $75.25 – Buffett’s ideal deep value, but unlikely to be reached without a crisis.
• Current status: The stock trades around $130 (as of early 2025) – roughly 14% below intrinsic value, but not enough of a safety margin to compensate for management’s capital allocation sins and disruption risk. Fairly valued, not cheap.

Verdict: WATCH

The moat is genuine and widening, but management dilutes owners with stock compensation and hides phantom earnings – a trust deficit that Buffett would not overlook. At $130, the price offers only a thin margin of safety against real structural threats (CGM disruption, price caps) that could permanently impair the highest‑margin segment. Wait for a 10–15% lower price ($112–$120) or a clearer signal that management will treat shareholders as partners before committing capital.